Drug intelligence / Profile preview

APT-103

Development stage: Unknown
Lead developer: APIE Therapeutics
Modality: Small Molecules

Overview

**APT-103** is a small molecule agonist of the apelin receptor (APLNR), a G protein-coupled receptor involved in regulating cardiovascular function, fluid homeostasis, and potentially metabolic processes. Developed by **Apie Therapeutics, Inc.**, it was designed to leverage APLNR activation for therapeutic benefit, though specific indications remain undisclosed in available data. The program has been discontinued, halting further clinical advancement.[3][5]

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on APT-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APT-103.

Explore the full profile